Treatment of bladder cancer is influenced by a number of factors including disease stage and histology. The swift entry of immune checkpoint inhibitors has transformed the treatment algorithm for bladder cancer; they are becoming entrenched options owing to their tolerability and impressive efficacy. Though platinum-based chemotherapy remains as standard, Merck & Co.'s PD-1 inhibitor, Keytruda, and Roche/Genentech's PD-L1 inhibitor, Tecentriq, are revolutionizing the treatment algorithm for advanced patients ineligible to receive standard cisplatin-based therapy.
- What percentage of non-muscle-invasive bladder cancer patients receives maintenance BCG, and how does this vary by stage and histologic grade?
- What is the uptake of immune checkpoint inhibitors in the United States? How are immune checkpoint inhibitors faring against older therapies (e.g., platinum-based chemotherapy)?
- How do drug-treatment rates vary across key patient populations?
- What are the main drivers and obstacles for treatment with key brands for unresectable locally advanced or metastatic bladder cancer?
Current Treatment: Provides physician insights on prescribing behavior, treatment paths, and the factors and perceptions driving brand usage so you can understand each brand’s performance and improve or defend your competitive position.
Markets covered: United States
Primary research: Survey of 100 U.S. medical oncologists fielded in April 2018.
Key companies: Merck & Co., Roche/Genentech, Bristol Meyers Squibb, AstraZeneca, Merck KGaA/Pfizer
Key drugs: Keytruda, Tecentriq, Opdivo, Imfinzi, Bavencio